KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得

Intravitreal aflibercept 8 mg in patients with neovascular age-related macular degeneration from China: 48-week results from the PULSAR trial.

Xiaodong Sun, Hong Dai, Youxin Chen, Xufang Sun, Liming Tao, Jun Xiao, Mei Han, Mingwei Zhao, Li Wang, Andrea Schulze, Ursula Maria Schmidt-Ott, Min Zhao, Xin Zhang, Zhaohong Wang, Sergio Leal, Wenbin Wei, PULSAR investigators

Int J Retina Vitreous 10.1186/s40942-026-00876-5

PMID42363252
PMCID-
DOI10.1186/s40942-026-00876-5
发表日期2026-06-26
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: PULSAR (NCT04423718) was a global, phase 3, randomized, double-masked, non-inferiority study of adults with neovascular age-related macular degeneration (nAMD). Patients were randomized 1:1:1 to receive aflibercept 8 mg every 12 (8q12), or 16 weeks (8q16), or aflibercept 2 mg every 8 weeks (2q8), following 3 initial monthly doses. This subgroup analysis investigated the efficacy and safety of aflibercept 8 mg vs. aflibercept 2 mg in patients from China with nAMD from the PULSAR trial. METHODS: This exploratory analysis evaluated the change from baseline in best-corrected visual acuity (BCVA), central retinal thickness (CRT), durability, and safety outcomes through week 48 in patients from China. All results were descriptive in nature. RESULTS: Least squares (LS) mean (95% confidence interval [CI]) change from baseline in BCVA at week 48 was + 13.2 (+9.0, +17.4), +9.7 (+5.8, +13.7), and + 10.0 (+6.9, +13.1) letters for patients from China in the 8q12 (n = 31), 8q16 (n = 31), and 2q8 (n = 39) groups, respectively. LS mean (95% CI) change from baseline in CRT (µm) at week 48 was -167 (-183, -151), -166 (-195, -137), and -180 (-195, -165) for patients in the 8q12, 8q16, and 2q8 groups, respectively. Randomized dosing intervals were maintained by 88.5% and 73.1% of patients in the 8q12 and 8q16 groups, respectively. The incidence of ocular treatment-emergent adverse events was similar across treatment groups. CONCLUSIONS: In patients with nAMD from China, aflibercept 8 mg administered over extended dosing intervals demonstrated efficacy and a safety profile consistent with that observed with aflibercept 2 mg, in line with the overall PULSAR cohort. TRIAL REGISTRATION: ClinicalTrials.gov, TRN NCT04423718. Registration date 8 June 2020.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。